Tag: pharmaceuticals

  • Genentech Gets Rights, Can Buy Out Biotech Research Program

    The biotechnology company Forma Therapeutics in Cambridge, Massachusetts says it has an agreement with Genentech, a member of the Roche Group, granting Genentech exclusive rights to acquire one of Forma’s pre-clinical small molecule cancer research programs. The specific cancer target of the therapy under development is not disclosed. The agreement begins as a research collaboration…

  • Neuromuscular Drug Gets Fast-Track, Orphan Approval

    Repligen Corp. in Waltham, Massachusetts says its drug candidate for spinal muscular atrophy received fast-track and orphan drug status from U.S. and European regulators. The U.S. Food and Drug Administration (FDA) granted fast-track status to Repligen’s RG3039, while the European Medicines Agency gave the drug its orphan medicinal product designation. Spinal muscular atrophy (SMA) is…

  • Pain Killer with Built-in Abuse Deterrence Gets FDA Clearance

    A prescription pain killing drug developed by Pfizer Inc. in New York and Acura Pharmaceuticals Inc. in Palatine, Illinois has received marketing approval from the U.S. Food and Drug Administration. Oxecta, an opioid analgesic tablet made from oxycodone hydrochloride (HCl), contains ingredients developed by Acura Pharmaceuticals to deter tampering that leads to misuse or abuse…

  • Calendar Blister Packs Shown to Help Medication Adherence

    A study of drug packaging indicates that calendar blister packaging with days or dates printed on the card under the individual dose helps patients keep to the prescribed schedule for those drugs. The results of the study appeared in the May 2011 issue of the journal Clinical Therapeutics (paid subscription required). Poor medication adherence leads…

  • Audion, Sanofi to Partner on Hearing Loss Therapies

    The French pharmaceutical company Sanofi and biotechnology company Audion Therapeutics in Amsterdam have agreed to develop potential treatments for hearing loss through through regenerative medicine and biologics. The collaboration will build on technology developed by Audion’s co-founder Albert Edge at the Massachusetts Eye and Ear Infirmary in Boston. Audion originally licensed Edge’s technology from Mass…

  • Pfizer Adds Mass. Institutions to Translational Network

    Pfizer Inc. in New York is adding eight Massachusetts research institutions to its network of translational research partnerships, called the Centers for Therapeutic Innovation. The company also says it will put the academic network’s headquarters in Boston, a $100 million investment over five years. Jose Carlos Gutierrez-Ramos, Pfizer’s vice-president for  biotherapeutics research and development, says…

  • Collaboration to Develop Second-Generation Malaria Vaccine

    The PATH Malaria Vaccine Initiative (MVI) says it has an agreement with Dutch biopharmaceutical company Crucell N.V., a division of Johnson & Johnson, and GlaxoSmithKline (GSK) to develop a second-generation vaccine against malaria. PATH is an international non-profit organization that helps communities worldwide break longstanding cycles of poor health. According to World Health Organization (WHO),…

  • Clinical Trial Tests Diuretic Drug on Neurologic Disorder

    A Michigan State University physician is testing a common diuretic as a treatment for a neurological disorder that affects younger, overweight women. The six-month clinical trial is funded by National Institutes of Health and conducted at 50 sites nationwide. Eric Eggenberger, professor of neurology and ophthalmology, is leading a team focusing on idiopathic intracranial hypertension…

  • Early Trial Evaluates Drug Combo for Blood Cancers

    Researchers at the Massey Cancer Center of Virginia Commonwealth University in Richmond have completed a phase 1 clinical trial evaluating a combination of the drugs Bortezomib and Alvocidib in patients with relapsed or refractory blood cancers. The team, which included contributors from several universities and research institutes, reported its results in the 15 May 2011…

  • Diagnostic Company to Partner with Scripps on Drug Discovery

    Molecular Response, a diagnostic services company in San Diego, California says it has an agreement with Scripps Genomic Medicine, part of the Scripps Translational Science Institute also in San Diego, for joint discovery of oncology and cardiovascular drugs. Molecular Response develops molecular diagnostics as a companion to targeted and personalized therapeutics. Under the terms of…